Be
Stock
Your Best Stock
Home
Stock Quotes
Markets
Stock Analysis
Broker Reviews
About
Stocks
›
Drug Manufacturers - General
›
GILD
Gilead Sciences
GILD
US equity
Market cap rank #81
Drug Manufacturers - General
CAR-T Therapy
Infectious Disease
Cancer Research
$151.03
−$0.34
(-0.22%)
Market open · Sep 24, 2:00 pm ET
After hours $151.37
0.00%
Open
$151.10
Prev close
$151.37
Day range
$149.69 – $152.97
Volume
2.55M
Market cap
$187.27B
P/E (TTM)
–
Dividend yield
2.13%
Overview
Technicals
Financials
Earnings
Valuation
Analysts
Dividends
Options
Ownership
News
Profile
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $160
Market news · 8 Sep 2026
Maxim Group Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $165
Market news · 8 Aug 2026
J.P. Morgan Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $160
Market news · 7 Aug 2026
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $160 to $174
Market news · 6 Aug 2026
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $150 to $177
Market news · 5 Aug 2026
Mizuho Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $170
Market news · 31 Aug 2026
Truist Financial Maintains Gilead Sciences(GILD.US) With Buy Rating
Market news · 28 Aug 2026
BMO Capital Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $174
Market news · 28 Aug 2026
Scotiabank Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $177
Market news · 28 Aug 2026
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $165
Market news · 21 Aug 2026
Barclays Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $145
Market news · 14 Aug 2026
Scroll to Top